LIDDS: Clarification regarding signed research agr
Post# of 301275
With reference to press release LIDDS signs research agreement with major European pharma company, published 21 July 2017 at 10:00 CET, we hereby announce that the agreement party is Ferring Pharmaceuticals.
Contact information Monica Wallter, CEO, monica.wallter@liddspharma.com , +46(0)73 7070 922
LIDDS is required to disclose the information in this press release under the European Union's Market Abuse Regulation and the Securities Market Act. The information was submitted through Monica Wallter, for publication on 24 July 2017 at 8:55 CET
About LIDDS LIDDS AB (publ) develops effective pharmaceutical products for cancer and other diseases with the patented NanoZolid® technology. NanoZolid® releases the medication locally and effectively which means significantly fewer side effects compared with systemic treatment. NanoZolid® technology allows for a controlled, sustained and customized release of medication for up to six months. NanoZolid® can integrate both small and large pharmaceutical molecules such as antibodies. The company's most advanced project, the prostate cancer product, Liproca® Depot containing 2-hydroxyflutamide, validates that the technology has a proven clinical effect. The prostate cancer project is currently in phase IIb. Industrial-scale production is produced in collaboration with Recipharm. LIDDS has active development projects where NanoZolid® is combined with antiandrogens, cytotoxic drugs and immuno-active agents. The LIDDS share is listed on Nasdaq, First North. Redeye AB is LIDDS certified adviser. For more information, please visit www.lidds.se .
Attachments:
(0)
(0)